Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Etoposide + Anlotinib in Advanced TNBC
NCT04452370Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Sep 2020
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in triple-negative breast cancer (TNBC), sponsored by Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
anlotinib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04452370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04452370.